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ARTICLE OPEN
The CloudUPDRS smartphone software in Parkinson’s study:
cross-validation against blinded human raters
Ashwani Jha1✉, Elisa Menozzi1,2, Rebecca Oyekan1,3, Anna Latorre1, Eoin Mulroy1, Sebastian R. Schreglmann1, Cosmin Stamate4,
Ioannis Daskalopoulos4, Stefan Kueppers4, Marco Luchini5, John C. Rothwell1, George Roussos 3 and Kailash P. Bhatia1✉
Digital assessments of motor severity could improve the sensitivity of clinical trials and personalise treatment in Parkinson’s disease
(PD) but have yet to be widely adopted. Their ability to capture individual change across the heterogeneous motor presentations
typical of PD remains inadequately tested against current clinical reference standards. We conducted a prospective, dual-site,
crossover-randomised study to determine the ability of a 16-item smartphone-based assessment (the index test) to predict
subitems from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III (MDS-UPDRS III) as assessed by three
blinded clinical raters (the reference-standard). We analysed data from 60 subjects (990 smartphone tests, 2628 blinded video MDS-
UPDRS III subitem ratings). Subject-level predictive performance was quantified as the leave-one-subject-out cross-validation
(LOSO-CV) accuracy. A pre-specified analysis classified 70.3% (SEM 5.9%) of subjects into a similar category to any of three blinded
clinical raters and was better than random (36.7%; SEM 4.3%) classification. Post hoc optimisation of classifier and feature selection
improved performance further (78.7%, SEM 5.1%), although individual subtests were variable (range 53.2–97.0%). Smartphone-
based measures of motor severity have predictive value at the subject level. Future studies should similarly mitigate against
subjective and feature selection biases and assess performance across a range of motor features as part of a broader strategy to
avoid overly optimistic performance estimates.
npj Parkinson’s Disease            (2020) 6:36 ; https://doi.org/10.1038/s41531-020-00135-w
INTRODUCTION
Precise and sensitive measures of the motor severity of
Parkinson’s disease (PD) remain elusive but critical if new
therapies are to be fairly and quickly evaluated. The internationally
validated, familiar and easily interpretable Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale Part III (MDS-
UPDRS III)1 continues to be the favoured primary endpoint of
major trials in PD2. But it is time-consuming for clinicians and its
poor calibration and sensitivity3 may have played a part in the
gross failure of novel therapies to translate into clinical practice4,5.
Mobile devices, such as wearables and smartphones, enable
low-cost objective repeated monitoring of motor severity that are
likely to improve the sensitivity of clinical trials in which they are
used as end-points. Digital assessments show promise6–8 but have
yet to be widely adopted partly due to the lack of transparency
and harmonisation of the analysis methods used and the lack of
subsequent high-quality subject-level evidence comparing them
to current reference-standard measures9.
Feasibility studies have reported that digital assessments
correlate with total MDS-UPDRS III8 and subcomponents of it6,10
but the equivalence of digital and clinical measures at the
individual level remains unclear. Cross-validated subject-level
prediction of disease category and total MDS-UPDRS III has been
demonstrated in ten patients7, but when scaled to larger numbers,
a model discriminating disease category—the simpler task—was
only accurate at the cost of unstable features11.
This failure to generalise may be due to three fundamental
reasons. First, digital models trained with single human scores
incorporate subjective bias within them, rather than removing it.
Second, approaches that consist of only 5–7 digital subtests may
be too blunt to capture the individual heterogeneity12 evident
within the 33-item clinical MDS-UPDRS III, and third, previous
studies are at high risk of providing over-optimistic results due to
feature selection bias if a large number of post hoc candidate
digital features or machine-learning algorithms are tested within a
limited size study.
We designed the CloudUPDRS Smartphone Software in
Parkinson’s (CUSSP) study to address these concerns. We assessed
the degree to which subject-level smartphone-based measures
predicted subject-level MDS-UPDRS III subitems. A randomised
crossover design and blinded assessment by three clinical raters
mitigated concerns about subjective bias. We used a larger 16-
item smartphone-based assessment to increase the capacity to
capture individual heterogeneity, and methods were pre-




Overall, 62 participants were recruited with a minority (5) from the
second site (Homerton University Hospital), which started recruit-
ment later. Network faults during data capture and storage errors
of video-recordings, or incorrect task performance (detected on
review of video-recordings) resulted in loss of data for two
subjects, 18/1008 remaining smartphone tests and 6/882 remain-
ing clinical MDS-UPDRS III items. Only three participants opted for
an OFF/ON recording, the treatment status of the remaining
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participants being considered intermediate. Subsequently, the
final analysis included 60 patients, 63 sessions, 990 smartphone
subtests, 876 MDS-UPDRS III item videos and 2628 human score
ratings. Twenty participants were female, eight participants were
left-handed. Demographic details are shown in Table 1 and
confirm that patients in this cohort were wide-ranging in age, had
prominent motor and non-motor symptoms, required moderate
amounts of medication and tended to remain functionally
independent without cognitive impairment (as selected by the
inclusion criteria). The total MDS-UPDRS III scores were skewed
towards the mild/moderate end, as expected given the inclusion
criteria. The subitems showing the greatest variation were left
finger tapping and left pronation/supination, whilst left and right
leg tremor showed very little variation (see Fig. 1). There was
significant inter-rater agreement between clinical raters in all
subitems at the population level, with rates of agreement mostly
ranging from moderate to substantial (apart from left pronation/
supination where agreement was only fair, see Table 2). Subject-
level inter-rater agreement analysis showed that all three blinded
clinical raters rarely completely disagreed (<5%, see Table 2).
Overall predictive accuracy of smartphone assessments
The primary outcome was the overall leave-one-subject-out cross-
validation (LOSO-CV) classification accuracy of the smartphone-
based prediction of the MDS-UPDRS III subscores. A fully
pre-specified analysis classified 70.3% (SEM 5.9%) of subjects into a
similar category to a clinical rater (see Fig. 2 and Supplementary
Table 4). This was above a random (36.7%; SEM 4.3%) baseline and
below the performance achieved with optimised classifier and
feature selection (78.7%, SEM 5.1%). Classifiers generally predicted
more than one category with notable exceptions where there was an
extreme degree of class imbalance within the clinical scores (left or
right leg tremor, left hand kinetic tremor; see Supplementary Table
4). Smartphone scores were poorer at predicting the median MDS-
UPDRS III subscores overall (57.0%, SEM 8.0%) but this was improved
with optimised classifier and feature selection (65.2%, SEM 7.5%; see
Supplementary Table 5).
Item-specific predictive accuracy of smartphone assessments
Item-specific LOSO-CV accuracy for each of the 16 smartphone
tests is shown in Fig. 3 and Supplementary Table 4. Notably
although classifier performance for tremor was universally high, in
the case of leg tremor (left leg tremor 97.0%, right leg tremor
97.0%), this was achieved by simply predicting the commonest
category consistently (very few participants had leg tremor). On
the other hand, bradykinesia scores had good variation across
subjects and the highest pre-specified analysis accuracies were
achieved for bilateral pronation/supination movements (left
74.6%, right 73.0%) and bilateral leg agility (left 63.5%, right
69.8%) rather than variants of finger tapping (1 target variant: left
53.2%, right 62.9%). The median-rater item-specific agreement
analysis followed a similar pattern but with generally lower
accuracy values; see Supplementary Table 5. The best-performing
classifiers for each were as follows: Radial Basis Function Support
Vector Machine for left hand rest tremor, right pronation/
supination; AdaBoost for right hand rest tremor, left fingertap (1
and 2 targets), right/left leg agility; Nearest Neighbours for left leg
rest tremor; Decision Tree for right leg rest tremor, left hand
postural tremor, and left/right hand kinetic tremor; Random Forest
for right hand postural tremor; Naïve Bayes for right fingertap (1
target); Linear Support Vector Machine for right fingertap (2
targets); Multinomial Logistic Regression for left pronation/
supination (see Supplementary Tables 2 and 3 for full details).
DISCUSSION
New measures of motor severity in PD must be robustly evaluated
at the subject level prior to widespread use. Although digital
assessments such as finger tapping speed are objective and more
likely to be reproducible, they can only be meaningfully
interpreted as severity scales either when matched to prima facie
valid subject-level outcomes such as degree of functional
dependence or, more commonly, when matched to well-
established and familiar but subjective scales such as the MDS-
UPDRS III. Subsequently, most digital tools trained on single
human classifications or ratings incorporate the subjective bias of
that particular rater within them6,8,10. Here, we mitigate against
this bias by training on the median of three blinded human ratings
with mostly moderate-to-substantial inter-rater agreement (see
Table 2), reducing the potential idiosyncratic influence of any
individual rater (i.e. over-fitting to a particular rater). This should
improve the subsequent generalisability of the smartphone-based
measures that have been developed here. We report that even
when generalised to out-of-sample subjects, classification of
CloudUPDRS smartphone measures was reasonably equivalent
to at least one of three MDS-UPDRS III human-raters overall (LOSO-
CV accuracy 70.3%; SEM 5.9%), and that individual subtests had
variable degrees of correspondence (Fig. 3 and Supplementary
Table 4). A more stringent analysis requiring smartphone-derived
measures to predict the median of three clinical raters exactly (a
requirement to perform better than any individual human rater)
was as expected less accurate overall (57.0%, SEM 8.0%) but still
better than a random baseline (28.5%, SEM 4.7%).
Any clinical study is limited by how well the study cohort
represents the clinical population in question. We analysed data
from 60 subjects which cannot represent the entire population
but compares favourably with other studies comparing supervised
smartphone measures to MDS-UPDRS III scores7,8,10. Our selection
criteria successfully captured those with mild to moderate disease
who may have mild/moderate depression or mild cognitive
impairment (MoCA > 20), but not of a severity that would impair
understanding of the simple motor tasks required. The sample is,
therefore, broader and more transparent than previous reports
and more representative of a typical secondary care population,
recruiting from two hospital sites and not excluding patients






Age (years) 68 51.6 80










PDQ-39 (range= 0–100) 32 6.6 77.9
Hoehn & Yahr (range 1–5) 2 2 2
MDS-UPDRS III (0–132)a 31.5 10.2 50.8
Note that minimum Hoehn & Yahr stage was 1, the maximum was 4, but
the frequency of these were low in this group.
aThe total MDS-UPDRS III score provided is from the clinical assessor who
performed the examination. Replacing individual subject subitem scores
with the median of their counterpart blinded video ratings, changes the
MDS-UPDRS III total population median to 26.5 (range 12–46).
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based on poor compliance with home monitoring, or phone
availability for example. In spite of this, some clinical features (e.g.
leg tremor) did not have enough sample variation to train a useful
predictive model, and generally models were more sensitive to
changes in mild to moderate (rather than severe) disease. This
highlights an important limitation to most current digital studies
that focus on mild/moderately affected individuals—if classifiers
are not trained on data from more severely affected patients (or
patients assess in the ‘OFF’ state), they will not generalise well to
these populations. In our study, only three subjects opted to be
assessed after overnight withdrawal from dopaminergic medica-
tion. Although the effect of treatment is not the question we are
addressing here, this may have limited the number of high MDS-
UPDRS III scores in our cohort. Similarly to other digital tools,
therefore, our smartphone software may be of most benefit to
populations with mild/moderate disease undergoing interven-
tions to modify disease progression or treat motor fluctuations.
Future work should aim to address this by collecting more data or
changing inclusion criteria to incorporate more severely affected
patients. Because all assessments were performed under clinical
supervision and reviewed by video, we can also have confidence
that the smartphone tasks were performed adequately without
undue influence from idiosyncratic factors (such as inadequate
understanding of the tasks, concurrent disabling dyskinesias or
distraction by a conversation). Although mild cognitive impair-
ment and depression may correlate with disease severity and
therefore slower movements, this is likely to equally affect the
clinical MDS-UPDRS III and smartphone subtests and therefore is
unlikely to be a significant confound to the primary outcome.
Finally, the reproducibility of these findings also depends on the
number of blinded clinical raters and their inter-rater agreement.
Our three blinded raters were of similar clinical experience and so
population-level and subject-level inter-rater agreement was
reasonable. Future work may look at the effect of a larger and
more varied pool of trained blinded raters.
PD is heterogeneous—the motor signs of tremor and bradyki-
nesia typically vary within a patient across body parts and over
time12. Most current digital assessments that focus on only 5–7
pre-selected subtests13–17 are likely to have reduced sensitivity as
compared to the 33-item MDS-UPDRS III. We rely on 16
independent smartphone subtests to evaluate individual hetero-
geneity across body parts and report results for individual tests in
addition to a combined score (see Figs. 2 and 3 and Supplemen-
tary Table 4). This allows for a closer match to the original MDS-
UPDRS III, but some tests (notably of rigidity and axial features)
remain currently outwith the scope of smartphone tests. Motor
features such as tremor amplitude can change over minutes and
so we explicitly randomised the order of smartphone and clinical
assessments (performed within minutes of each other) across
patients to avoid systematic biases in measurement present in
other studies. We found that clinical tremor scores were predicted
well by subject-level smartphone measures (LOSO-CV accuracy 46
−97%) in keeping with its importance in previous studies18,19, but
that in the case of leg tremor, this was largely due to low variation
in the sample of MDS-UPDRS III tremor scores. Without collecting
additional functional outcome data, however, it remains unclear
whether this apparent insensitivity of the MDS-UPDRS III tremor
classification has a clinically meaningful significance. Bradykinesia
tests also showed variable performance with pronation/supination
measures standing out as having good sampling variance across
the population and good subject-level correspondence between
clinical and digital measures (mean LOSO-CV accuracy 73–74.6%).
This is an important consideration for current smartphone
assessments that typically focus on finger-tapping only13–16.
Future analyses should determine whether a combination of
subtests can be used to predict non-tested items (such as limb
rigidity) or approximate total MDS-UPDRS III score but this is
Fig. 1 Clinical MDS-UPDRS III score subitem distributions. Distributions show a skew towards lower values consistent with other studies of
early and moderate disease. Some clinical features (notably Left and Right Leg Tremor) show poor variation within this sample of 60
individuals with Parkinson’s.
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beyond the scope of the pre-specified analysis plan that we report
here. Until this is established, we suggest ongoing assessment of a
broader range of motor tests to improve the sensitivity of subject-
level smartphone-based measures to diverse motor presentations
of disease.
Conversion of a raw digital measurement into a useful digital
biomarker typically requires specific data selection and transfor-
mation (feature selection) and choice of an optimal machine-
learning algorithm. The greater the pool of post hoc features and
algorithms from which the selection takes place, the greater the
risk of feature selection bias where predictive accuracy is over-
optimistic and relies on chance relations in the data (also known
as ‘over-fitting’). This problem is magnified when the ratio of
features to observations is high and may explain why previous
models failed to generalise11. We mitigated against this by pre-
registering our design and features6 and using a standard linear
classification algorithm. Our approach, based on more restrictive
pre-specified analysis and the consideration of individual features
only, is conservative compared to the majority of prior studies in
the literature. We additionally performed an exploratory graded
feature and classifier selection process which maximally led to an
improved overall LOSO-CV accuracy of 78.7% (SEM 5.1). The
combined results provide conservative and relatively unbiased
benchmark accuracies suitable for clinical translation (full pre-
specification) together with increasingly optimised results which
are at risk of bias, but facilitate comparison with other studies and
suggest optimal features and classifiers to be tested by future
research.
This study demonstrates how digital assessments for PD can be
robustly validated within prospective clinical trials—a necessary
step prior to widespread adoption. We mitigated against prior
concerns of subjective bias and feature selection bias whilst
remaining sensitive to the diverse motor presentations of the
condition and utilising open-source analysis software. Our
evaluation provides a conservative but relatively unbiased bench-
mark performance of how smartphone-based measures corre-
spond to standard-reference measures at the subject level. Future
smartphone-based studies should consider similar precautions
and incorporate more severely affected patients to improve the
reliability and generalisability of their conclusions.
METHODS
Study design
We designed and conducted a prospective, pre-registered (NCT02937324),
dual-site crossover-randomised study comparing structured single time-
point smartphone-based and blinded clinical rater assessments of motor
severity in PD. The primary outcome was the degree to which subject-level
smartphone-based measures predicted subject-level MDS-UPDRS III as
calculated by three blinded clinical raters. This was quantified as the
Table 2. Population-level and subject-level inter-rater agreement for clinical MDS-UPDRS III subscores.
Subtest Number of categories Kappa (SEM) 95% confidence interval Agreement p value Subject-level agreement (a/b/c)
Left hand rest tremor 4 0.68 (0.06) 0.65−0.71 Substantial <0.00001 96.7/1.6/1.6
Right hand rest tremor 4 0.62 (0.06) 0.58−0.65 Substantial <0.00001 72.6/27.4/0
Left leg rest tremor 3 0.58 (0.07) 0.54−0.61 Moderate <0.00001 93.5/6.45/0
Right leg rest tremor 3 0.72 (0.06) 0.69−0.75 Substantial <0.00001 82.5/17.5/0
Left hand postural tremor 4 0.76 (0.06) 0.73−0.79 Substantial <0.00001 79.3/20.6/0
Right hand postural tremor 4 0.75 (0.06) 0.72−0.78 Substantial <0.00001 82.5/17.5/0
Left hand kinetic tremor 3 0.62 (0.07) 0.59−0.66 Substantial <0.00001 69.8/30.2/0
Right hand kinetic tremor 3 0.45 (0.07) 0.41−0.49 Moderate <0.00001 61.9/38.1/0
Left fingertap 5 0.54 (0.04) 0.52−0.56 Moderate <0.00001 50.0/48.4/1.6
Right fingertap 4 0.64 (0.05) 0.61−0.66 Substantial <0.00001 64.5/35.5/0
Left pronation/supination 5 0.42 (0.05) 0.40−0.44 Moderate <0.00001 42.9/52.4/4.8
Right pronation/supination 4 0.37 (0.05) 0.34−0.39 Fair <0.00001 42.9/52.4/4.8
Left leg agility 5 0.55 (0.05) 0.53−0.58 Moderate <0.00001 57.1/41.3/1.6
Right leg agility 4 0.57 (0.06) 0.54−0.60 Moderate <0.00001 61.9/38.1/0
The population-level inter-rater agreement for each MDS-UPDRS III subscore was calculated using Fleiss’ Kappa. This ranges from −1 to 1, where 0 indicates
chance agreement, 1 indicates complete agreement, and −1 indicates complete disagreement. Kappa values are shown for each subtest along with standard
error of the mean (SEM) and 95% confidence intervals. The number of categories available in the sample (of all raters) is also shown. All estimates of
agreement were highly significant. The subject-level agreement was calculated as the percentage of subjects where the blinded rating clinicians (a) agreed
completely (3 raters agreed), (b) agreed moderately (2 raters agreed) or (c) disagreed (all 3 ratings were different). This is shown as a/b/c in the table above.
Complete disagreement was rare (<5% in all subitems).
Fig. 2 Primary outcome (any-rater criterion). The mean leave-one-
subject-out cross-validation (LOSO-CV) classification accuracy of the
smartphone-based prediction of the blinded MDS-UPDRS III. The
accuracy of a number of approaches is compared to a random
baseline (similar to rolling a dice where subjects were randomly
assigned to a clinical category). The fully pre-specified analysis (blue)
relied on pre-published features and a standard multinomial
regression model. The Best Classifier approach selected the best
classifier from a range based on best performance but used only the
pre-specified features. The Best Feature approach selected the best
feature from a range but used only the pre-specified classifier. The
Best Classifier and Feature approach selected the best combination
of both. Approaches are graded according to the risk of selection
bias: the pre-specified analysis has a very low risk, the Best Classifier
or Best Feature analyses have low risk whilst the combination
approach has a moderate risk of over-optimistic accuracy. Error bars
represent SEM.
A. Jha et al.
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leave-one-subject-out cross-validation (LOSO-CV) predictive accuracy. This
work has received ethical approval from the UK HRA and the local research
ethics committee and written informed consent was obtained from all
participants.
Participants
Participants were recruited from both the National Hospital for Neurology
and Neurosurgery, London, UK and Homerton University Hospital, London,
UK between 8 August 2017 and 1 March 2019. The inclusion criteria were
(1) diagnosis of probable idiopathic PD according to Brain Bank criteria20,
(2) age over 18 years old, (3) a score >20/30 on the Montreal Cognitive
Assessment (MoCA)21, (4) no anti-parkinsonism medication changes within
the last week, (5) capacity to consent, (6) ability to understand English well
enough to operate the phone software, follow its instructions and be able
to answer the study questions. Exclusion criteria were: (1) concurrent acute
medical illness, (2) other co-morbidity that in the opinion of the
Investigator may preclude their participation in the study, (3) inability to
consent. A target of 60 participants was pre-specified based on feasibility
rather than a power calculation.
Fig. 3 Individual Test Prediction Accuracy (any-rater criterion). The leave-one-subject-out cross-validation (LOSO-CV) classification accuracy
of individual subtest smartphone-based prediction of the blinded MDS-UPDRS III subitems. Baselines and models are described in the legend
to Fig. 2. Subtests relate to the corresponding MDS-UPDRS III subitems. Note that the Finger tapping MDS-UPDRS III subitem is repeated
because it is predicted by two smartphone tasks (one or two target tapping).
A. Jha et al.
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Clinical data collection
Patient data were collected over one or two visits, as individually
convenient. Screening assessments performed after enrolment included
the full MDS-UPDRS1, MoCA21, Beck Depression Inventory22, PDQ-3923 and
Hoehn and Yahr24. Participants opted to perform the motor assessments
immediately, or at a second morning visit after overnight withdrawal of
their anti-parkinsonian medications. Participants attending for a second
visit performed the test initially in a practically defined ‘OFF’ state, and
then took their usual medication and repeated the testing in the ‘ON’ state.
The latter test was carried out after a maximum of 1.5 h from the initial
testing and only after both the examiner and participant agreed that the
participant had entered the ‘ON’ state. Participants attending for only one
visit were labelled as an ‘Intermediate’ state.
Each motor assessment included a standard video-recorded assessment
of the 33-item MDS-UPDRS III1 by a member of the movement disorder
clinical team and a 16-item smartphone-based assessment supervised by
the clinician. Smartphone assessments were performed on either the
participant’s own phone or on a smartphone supplied by the study team
depending on availability. The smartphone and clinical assessments were
performed one immediately after the other in a crossover design—their
order randomised by software within the CloudUPDRS application at the
point of enrolment for each participant.
Blinded clinical video evaluation
In addition to the live clinical MDS-UPDRS III ascertained by the examining
clinician, we also obtained three blinded rater scores to mitigate against
subjective rater bias. Three neurologists with at least 12 months of
specialist movement disorders training post certification who were not
involved with the initial data collection, separately rated the videoed
examination of each MDS-UPDRS III subcomponent included in the study
(3.4 Finger tapping, 3.6 Pronation/supination movements of hands, 3.8 Leg
agility, 3.15 Postural tremor of hands, 3.16 Kinetic tremor of hands, 3.17
Rest tremor amplitude; see Supplementary Table 1 for further details)
blinded to the medication status, crossover randomisation order and
clinical details of the participant and to each others’ scores.
The CloudUPDRS system
The CloudUPDRS system is a CE marked software device consisting of the
CloudUPDRS application for Android smartphones, a cloud-based scalable
data-collection service and a data-mining toolkit that we developed
(Manufacturer: Birkbeck College, University of London, MHRA Manufac-
turer’s Ref. number CA015327, Class 1a Medical Device, date: 29/2/
16)6,25,26. The graphical-user-interface has been iteratively improved over a
number of design cycles with the input of patient-led focus groups,
clinicians and user-interface design experts to improve user experience in
the target population, many of whom have impaired visual perception and
dexterity. As far as possible it is also designed to harmonise data collection
across multiple device types (e.g. by preserving distance and size of
tapping targets)26. The software guides each participant through
17 subtests that correspond to subcomponents of the MDS-UPDRS III.
Each subtest has specific written, visual and audio instructions (available at
http://www.updrs.net/help/) and lasts between 60 and 90 s during which
time the relevant phone sensor is recorded at the maximum sampling rate
the phone allows (minimum of 50 Hz). Raw sensor data are time-stamped,
assigned a unique identification number and stored locally. On completion
of the test subsets, data are automatically uploaded to a remote secure
server via an encrypted link. Full computational details have been
published previously25,26.
Smartphone data collection
Smartphone subtests were designed to resemble the MDS-UPDRS III as far
as possible, whilst also considering safety and practicality in the context of
concurrent smartphone use. Three types of subtests were performed.
Finger tapping required participants to tap one or two consistently spaced
targets on the smartphone whilst screen sensors recorded the onset,
duration, upwards or downwards movement and the coordinates of each
touch. Tremor and proximal limb bradykinesia tests required the
participant to hold or repeatedly move the phone in a stereotyped
pattern whilst acceleration in 3- or 6-axes was recorded. Walking tests
required the participant to place the phone in their pocket and walk 5 m,
turn around and walk back (however note that gait analysis was not part of
the pre-specification and so has been excluded from the current report).
Supplementary Table 1 shows the correspondence between each MDS-
UPDRS III item and each CloudUPDRS subtest, and gives details of sensors
used, recording times and the features extracted. Note that the clinical
MDS-UPDRS III subitem Finger tapping is assessed with two separate
smartphone test items per hand (One Target Finger Tapping and Two
Target Finger Tapping). Participants were not given any specific training
and were asked to follow the onscreen instructions when performing
smartphone tasks. In some cases, examiners emphasised the aspects of the
instruction to ensure the task was performed correctly (e.g. ‘with your left
hand first’, ‘tap as fast as you can for 1 min’). All smartphone examinations
were also video-recorded and reviewed to confirm correct task perfor-
mance. Trials where there were substantial errors, such as unintended use
of wrong hand, were removed.
Smartphone data preprocessing and feature extraction
Raw data were stored in a custom flat text files and processed offline using
PDkit version 1.2.1 (https://github.com/pdkit/pdkit), an open-source data
science toolkit for PD running in a Python 3 environment that has been
previously developed by some of the authors of this study. Data were
ingested and converted to a standardised time-series data type. There are
many ways in which subject-level acceleration time-series data and touch
event data can be summarised by single numbers (features). For example,
acceleration data can be characterised by the power at its peak frequency
or the amplitude over a frequency range. Touch event data can be
summarised as a function of the hold-time of a tap, the time between taps
or the spatial proximity of the touch to the visual target. PDKit provides
robust, transparent and automated extraction of hundreds of distinct
features currently in use in the literature and is designed to support
harmonisation and comparison of metrics within one fully transparent and
non-proprietary platform. We calculated nine features for finger tapping
subtests, and 35 features for each other subtest. A persistent archive of
feature names and the code used to calculate them is available at: https://
doi.org/10.5281/zenodo.3632529.
Pre-specified features
We separately report analyses of pre-specified features (from our
previously reported study6) and the best-performing feature for each
subtest (see below). Pre-specified features were calculated exactly as
previously. That is, for tremor subtests, the magnitude of the scalar sum
acceleration in three axes was filtered with a high-pass second-order
Butterworth filter at 2 Hz prior to fast Fourier transform. Tremor amplitude
was calculated as the sum of the resultant power spectrum between 2 and
10 Hz. For bradykinesia assessments excluding tapping tests, the signal
had DC removed prior to applying a low-pass second-order Butterworth
filter at 4 Hz and subsequent fast Fourier transform. The amplitude of the
remaining signal was calculated as the sum of the amplitude between 0
and 4 Hz. Note that in this context, amplitude relates to the ‘magnitude’ of
tremor in the frequency domain rather than the measured distance
travelled during movement. For single- or dual-tapping tests we calculated
the tapping frequency as the total number of taps divided by the time
period of the task (60 s).
Graded approach to mitigating feature and classifier selection bias
With many more features available than observations, post hoc selection of
one or a few of these features is a commonly used strategy to improve
model stability. This can, however, subsequently induce feature selection
bias. Post hoc selection of a classifier can induce a similar bias and so we
adopted a graded approach to address both issues. At the conservative
end, we used single pre-specified features from our previously reported
study6 and standard statistical classifiers (multinomial logistic regression)
maximally free from bias but likely to under-fit the data (under-optimistic
accuracy). At the exploratory end, we selected both the feature and
classifier with maximum out-of-sample predictive accuracy which is
moderately likely to over-fit the data (over-optimistic accuracy). Inter-
mediate accuracy values where either the classifier or the feature were
selected based on performance are also presented. A full description of the
feature and classifier selection process and details of the pre-specified
features are presented in Supplementary Note 2. Additionally, all available
features and the accompanying software implementation can be viewed in
the PDkit online documentation (https://pdkit.readthedocs.io/).
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Statistical analysis
The primary outcome was the overall LOSO-CV classification accuracy of
the smartphone-based prediction of selected subitems of the MDS-UPDRS
III (3.4 Finger tapping, 3.6 Pronation/Supination movements of hands, 3.8
Leg agility, 3.15 Postural tremor of hands, 3.16 Kinetic tremor of hands,
3.17 Rest tremor amplitude). For each subject, each item from the MDS-
UPDRS III was blindly rated three times and so the median of these clinical
ratings was taken forward as the dependent variable for model training.
For each of the 16 smartphone subtests, a single (normalised) smartphone
feature was entered into a classifier using the corresponding median MDS-
UPDRS III subscore as the target variable. The target score maximally
consisted of five categories reflecting the ordinal 5-point scale of each
MDS-UPDRS III item, and often consisted of fewer categories being
restricted to measures in the study population sample. To reduce the risk
of over-fitting and to understand how classifiers would perform on new
unseen subjects, we performed LOSO-CV. The out-of-sample prediction for
each subject was therefore made from a model trained only on the
remaining data. Correct classification was defined as an individual
prediction consistent with any of the three individual clinical raters (any-
rater criterion). We additionally performed a more stringent analysis in
which correct classification was defined as an individual prediction
consistent with the median of three individual clinical raters (median-rater
criterion). Higher accuracy can reflect characteristics of the target
distribution (the distribution of MDS-UPDRS III item scores) such as class
imbalance, rather than the utility of the smartphone data and so we
performed two additional checks. First, we determined whether the pre-
specified models were predicting a range of categories rather than
consistently predicting one category. Secondly, we provide a reference
‘random baseline’ accuracy from a classifier that randomly assigns subjects
into each available clinical category with uniform probability across
categories. As well as using pre-specified features and the standard
multinomial logistic regression model, we tested a number of other feature
and classifier combinations using the same LOSO-CV procedure (see
Supplementary Note 2).
To ensure the three blinded clinical raters were consistent with each
other, we additionally calculated inter-rater reliability for each MDS-
UPDRS III subscore using Fleiss’ Kappa, which is a generalisation of
Cohen’s Kappa to more than two raters27. Kappa ranges from −1 to 1,
where 0 indicates chance agreement, 1 indicates complete agreement,
and −1 indicates complete disagreement at the population level. We
also provide a measure of subject-level inter-rater agreement. This was
calculated for each MDS-UPDRS III subscore as the percentage of
subjects where the blinded rating clinicians agreed completely (3 raters
agreed), moderately (2 raters agreed) or disagreed (all 3 ratings were
different). Inter-rater agreement was calculated in Matlab R2020a (The
MathWorks Inc, Natick, MA, USA) using the Fleiss toolbox (https://www.
github.com/dnafinder/Fleiss).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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